<DOC>
	<DOCNO>NCT02182869</DOCNO>
	<brief_summary>Study evaluate safety combivent deliver two different formulation ( hydrofluoroalkane ( HFA ) chlorofluorocarbon ( CFC ) ) meter dose inhaler ( MDI ) , use cumulative dose response model patient COPD .</brief_summary>
	<brief_title>Combivent速 HFA-propelled Compared CFC-propelled Metered Dose Inhaler Patients With COPD ( Chronic Obstructive Pulmonary Disease )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>1 . Male female patient 40 year age old 2 . A diagnosis COPD define American Thoracic Society ( ATS ) criterion . Patients must relatively stable , moderate severe airway obstruction baseline FEV 1 &lt; =65 % predict normal FEV1/FVC &gt; =70 % . 3 . A smoking history ten packyears . A packyear defined equivalent smoke one pack 20 cigarette per day year 4 . Able perform technical satisfactory pulmonary function test 5 . Able trained proper use MDI 6 . Having sign informed consent prior participation trial 7 . Affiliation French social security system beneficiary system 1 . Significant disease COPD . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study 2 . Clinical relevant abnormal baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion , patient exclude 3 . Serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 80 IU/L ; serum glutamic pyruvic transaminase ( SGPT ) &gt; 80IU/L , bilirubin &gt; 2.0mg/dL creatinine &gt; 2.0mg/dL 4 . Serum potassium level normal range 5 . Total blood eosinophil count &gt; =600/mm続 6 . Recent history ( i.e. , one year less ) myocardial infarction 7 . Recent history ( i.e. , three year less ) heart failure cardiac arrhythmia require drug therapy 8 . History cancer , treat basal cell carcinoma , within last five year 9 . History lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis 10 . History thoracotomy pulmonary resection . History thoracotomy reason evaluate per exclusion criterion . 1 11 . History asthma , allergic rhinitis atopy 12 . History active alcohol drug abuse 13 . Known active tuberculosis 14 . Upper respiratory tract infection COPD exacerbation six week prior screen visit screen visit visit 2 15 . Known symptomatic prostatic hypertrophy bladder neck obstruction 16 . Known narrowangle glaucoma 17 . Current significant psychiatric disorder 18 . Regular use daytime oxygen therapy 19 . Use betablocker medication , monoamine oxidase inhibitor tricyclic antidepressant 20 . Use cromolyn sodium nedocromil sodium 21 . Use antihistamine . 22 . Use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose screen visit change screen visit visit2 ) dose excess equivalent 10 mg prednisone per day 20mg every day 23 . Use oral betaadrenergics longacting betaadrenergics salmeterol ( Serevent速 ) formoterol two week prior screen visit screen visit visit 2 24 . Changes therapeutic plan within last six week prior screen visit screen visit visit 2 , exclude change long act oral betaadrenergics short act inhaled betaadrenergics purpose trial 25 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception 26 . Known hypersensitivity anticholinergic betaagonist drug component either Combivent速 formulation 27 . Use investigational drug within one month six half life prior screen visit 28 . Previous participation study 29 . Patient deprive freedom judicial administrative decision 30 . Patient leave medical social establishment 31 . Patient hospitalize mental disorder without ( ) consent 32 . Patient guardianship 33 . Patient emergency situation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>